Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 512 for:    ESCITALOPRAM AND Serotonin Uptake

ECT Schizophrenia Serotonin Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00278668
Recruitment Status : Unknown
Verified May 2008 by Sha’ar Menashe Mental Health Center.
Recruitment status was:  Not yet recruiting
First Posted : January 18, 2006
Last Update Posted : May 21, 2008
Sponsor:
Information provided by:
Sha’ar Menashe Mental Health Center

Tracking Information
First Submitted Date January 16, 2006
First Posted Date January 18, 2006
Last Update Posted Date May 21, 2008
Study Start Date October 2006
Primary Completion Date Not Provided
Current Primary Outcome Measures Not Provided
Original Primary Outcome Measures Not Provided
Change History Complete list of historical versions of study NCT00278668 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title ECT Schizophrenia Serotonin Study
Official Title Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy
Brief Summary We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT
Detailed Description We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Schizophrenia
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: January¬†16,¬†2006)
15
Original Enrollment Same as current
Estimated Study Completion Date October 2006
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).

Ages 18 -55 Men and/or women -

Exclusion Criteria:

  1. History of neurological disorders, active substance abuse in the previous 3 months.
  2. Estimated IQ less then 70.
  3. SSRIs treatment 4 weeks prior to the study.
  4. Any subject suffering from inflammatory fever disease will be excluded from the study.

    -

Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT00278668
Other Study ID Numbers 123.ctil
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Sha’ar Menashe Mental Health Center
Collaborators Not Provided
Investigators
Principal Investigator: Avi Peled, MD Shaar Menashe MHC
Principal Investigator: Ilan Modai, M.D. MHA Shaar Menashe
Principal Investigator: Moshe Rehavi, Ph.D. TAU
PRS Account Sha’ar Menashe Mental Health Center
Verification Date May 2008